Close Menu

NEW YORK – BioMérieux reported Wednesday that its fourth quarter revenues rose 21 percent year over year.

For the three months ended Dec. 31, BioMérieux reported revenues of €852.6 million ($908.2 million), up 14 percent on a reported basis, or 21 percent at constant exchange rates and scope of consolidation, from €746.8 million in the prior-year period.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.